Investors Research Corp’s Actinium Pharmaceuticals ATNM Stock Holding History

Investors Research Corp’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$294	Hold	300	–	–	﹤0.01%	771
2026 Q1	$299	Hold	300	–	–	﹤0.01%	812
2025 Q4	$408	Hold	300	–	–	﹤0.01%	815
2025 Q3	$480	Hold	300	–	–	﹤0.01%	836
2025 Q2	$420	Buy	300 +50	+20%	+$75	﹤0.01%	889
2025 Q1	$403	Buy	+250	New	+$317	﹤0.01%	923

Other funds holding ATNM

AIS

AM Investment Strategies Chattanooga, Tennessee $521M AUM 33.22% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

PAI

Pittenger & Anderson Inc Lincoin, Nebraska $2.79B AUM 12.81% 1-Year Est. Return

APW

Allied Private Wealth Boca Raton, Florida $156M AUM

Investors Research Corp's ATNM Position: Q2 2026 in Review

Investors Research Corp held its Actinium Pharmaceuticals (ATNM) position steady in Q2 2026 at 300 shares worth $294. The position accounts for ﹤0.01% of the portfolio, ranked #771.

Investors Research Corp first reported a position in ATNM in Q1 2025 and has held it in 6 quarters since. The position peaked at $480 in Q3 2025. 5 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

Investors Research Corp held 300 shares of Actinium Pharmaceuticals worth $294 as of Q2 2026.
Investors Research Corp left its Actinium Pharmaceuticals share count unchanged in Q2 2026.
Actinium Pharmaceuticals made up ﹤0.01% of Investors Research Corp's portfolio in Q2 2026, its #771 holding.
Investors Research Corp first reported a position in Actinium Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Investors Research Corp's Actinium Pharmaceuticals position peaked at $480 in Q3 2025.
5 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Investors Research Corp's 13F filing for Q2 2026, filed 10 Jul 2026.